Summary & Overview
HCPCS Q9977: Compounded Drug, Not Otherwise Classified
HCPCS Level II code Q9977 designates a compounded drug that does not fall under a more specific HCPCS descriptor. Compounded medications play an important role when commercially available products do not meet a patient’s clinical needs—such as customized dosages, alternative formulations, or combination therapies—but their variable nature creates billing and coverage complexity at the national level. This overview addresses the use and billing of Q9977 across major payers and public programs.
Key payers referenced include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, typical sites of service, and where it fits within pharmacy service lines. The publication summarizes benchmark considerations, common coverage questions, and relevant payment policy themes that affect how compounded drugs are processed and reimbursed. It also highlights common documentation and billing topics associated with non-routine compound claims.
The content is intended for revenue cycle, pharmacy billing, and policy professionals seeking a national primer on Q9977—what it denotes, why it matters in clinical and billing workflows, and the types of questions payers and auditors often address when compounded products are billed.
Billing Code Overview
HCPCS Level II code Q9977 represents compounded drug, not otherwise classified. This code is used for reporting compounded pharmaceutical preparations that do not have a specific HCPCS Level II descriptor.
Service Type: Pharmacy/Drug Compound Preparation
Typical Site of Service: Outpatient pharmacy or facility pharmacy compounding area, and may apply when compounded medications are furnished in ambulatory settings or billed by institutional pharmacies.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an outpatient receiving a physician-ordered, office- or pharmacy-compounded medication that is not available as a single FDA‑approved product. Examples include individualized topical preparations for dermatologic conditions, hormone- or pain-management topical creams, or small-volume sterile parenteral admixtures prepared for an allergic patient with unique sensitivities. The clinical workflow begins with a clinician evaluating the patient and documenting the medical necessity and formulation specifics in the chart, including diagnosis, dose, route, and directions. A prescription or compounding order is sent to an in‑house or external compounding pharmacy. The pharmacy compounds the product per the prescriber’s order, performs appropriate quality checks and labeling, and returns the medication to the clinic or ships to the patient. Billing staff or the dispensing pharmacy submits HCPCS code Q9977 for the compounded drug (not otherwise classified) with the associated NDC or ingredient list and the patient’s ICD-10 diagnosis. Typical sites of service include outpatient clinic infusion centers, physician offices, retail or specialty compounding pharmacies, and ambulatory surgical centers when compounded agents are used peri‑procedurally. The service commonly applies to patients with individualized dosing needs, allergies to standard formulations, or when commercially available products are discontinued or unavailable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when an E/M visit is performed on the same day the compounded medication is administered and documentation supports separate, distinct E/M work |
59 | Distinct procedural service | Use to indicate a service or procedure that is distinct or independent from other services performed on the same day (e.g., separate injection site or distinct compound administration) |
EP | Ordering/Referring Physician | Use when reporting the physician who ordered the compounded drug on claims that require ordering physician identification |
LB | Drug administered is limited by beneficiary cost‑sharing (e.g., manufacturer assistance) | Use when the compounded product is subject to a specific benefit/coverage handling that affects cost sharing |
JW | Drug or biological amount discarded/not administered | Use when documenting and billing for discarded portion of a compounded sterile preparation per payer rules when applicable |
KX | Requirements specified in medical policy have been met | Use when payer policy requires attestation of medical necessity or coverage criteria for the compounded medication |
GA | Waiver of liability statement on file (patient unable to pay) | Use when a voluntary ABN/waiver is on file per payer requirements |
GP | Services delivered under an integrated outpatient physical therapy plan of care | Use for therapy-related compounded topical formulations when therapy plan supports the compound |
QW | CLIA waived test (for drug assay services when used to verify compound) | Use when a waived point‑of‑care assay is performed as part of compounding quality checks (rare) |
XC | Services not normally reported together — distinct procedural service | Use similarly to modifier 59 when payers require more granular modifier reporting |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207Q00000X | Internal Medicine | Common prescribers for individualized systemic compounded formulations |
207RC0000X | Dermatology | Frequent prescribers for topical compounded preparations for dermatologic conditions |
363LP0800X | Pharmacy | Compounding pharmacists responsible for preparation and dispensing of Q9977 products |
208000000X | Family Medicine | Primary care prescribers who order individualized compounded medications for chronic conditions |
164W00000X | Pain Management | Specialists prescribing compounded topical or parenteral analgesic blends |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
L30.9 | Dermatitis, unspecified | Common indication for individualized topical compounded creams when commercial topical formulations are ineffective or contraindicated |
M54.5 | Low back pain | Indication for compounded topical analgesic preparations used adjunctively for localized pain management |
E28.2 | Polycystic ovarian syndrome | May require individualized compounded hormone formulations when standard therapies are unsuitable |
J45.40 | Moderate persistent asthma, uncomplicated | Potential indication for a compounded inhalation solution when commercial inhalants are not tolerated or are unavailable |
B34.9 | Viral infection, unspecified | Possible indication for topical or oral compounded antiviral formulations in select clinical scenarios |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
96372 | Therapeutic, prophylactic, or diagnostic injection (subcutaneous or intramuscular) | Used when a compounded injectable is administered in clinic by a clinician or nurse following compounding of the drug billed with Q9977 |
96409 | Chemotherapy administration, intravenous push, single or initial substance/drug | Used when a compounded chemotherapeutic agent is prepared and administered IV in an oncology ambulatory setting |
99070 | Supplies and materials (devices, implants, medicines, etc.) provided by physician over and above those usually included with the office visit | Used to capture additional non‑billable supply costs associated with administration or handling of the compounded product when payer allows |
94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction; administration | Used when a compounded inhalation solution is prepared and administered in clinic |
96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | Used when a compounded intravenous infusion is administered and infusion services are billed alongside the compounded medication |
99024 | Postoperative follow-up visit, included in global period | Used in documentation workflows when postoperative management includes use of a compounded topical or systemic medication |